MDGL
MADRIGAL PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$399.63
+0.84%Next report
Analyst consensus
- Next report date
- Feb 18, 2027
- EPS estimate
- $1.20
- Revenue estimate
- $474.7M
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- $1.83
- EPS estimate
- -$0.86
- Revenue actual
- $431.3M
- Revenue estimate
- $404.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -1544.3%
- Revenue beats (12Q)
- 5
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.86 | $1.83 | Beat 312.01% | $431.3M |
| Jul 30, 2026 | -$2.68 | -$1.99 | Beat 25.75% | $364.3M |
| May 6, 2026 | -$3.61 | -$3.25 | Beat 9.97% | $311.3M |
| Feb 19, 2026 | $0.04 | -$2.57 | Miss -6525.00% | $321.1M |
| May 1, 2025 | -$3.62 | -$3.32 | Beat 8.29% | $137.3M |
| Feb 26, 2025 | -$4.32 | -$2.71 | Beat 37.27% | $103.3M |
| Oct 31, 2024 | -$6.94 | -$4.92 | Beat 29.11% | $62.2M |
| Feb 28, 2024 | -$5.32 | -$5.68 | Miss -6.77% | $770.0K |
| Feb 23, 2023 | -$4.41 | -$4.98 | Miss -12.93% | — |
| Nov 3, 2022 | -$4.05 | -$4.75 | Miss -17.28% | — |
| Aug 4, 2022 | -$3.76 | -$4.14 | Miss -10.11% | — |
| Feb 24, 2022 | -$3.92 | -$3.78 | Beat 3.57% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 18, 2027